Welcome to our dedicated page for HEMOSTEMIX news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on HEMOSTEMIX stock.
Hemostemix Inc. reports developments tied to its autologous blood-based stem cell therapy platform, including VesCell™ (ACP-01), a patient-derived angiogenic cell therapy associated with ischemic and vascular-related conditions. Company news commonly covers clinical-study history, published results, FDA interactions, physician education, and commercialization activity in markets such as Florida, Canada, and The Bahamas.
Recurring updates also include private placements and other capital actions, leadership and scientific-advisory appointments, shareholder and governance matters, and regulatory planning for ACP-01 across indications including peripheral arterial disease, chronic limb threatening ischemia, angina, cardiomyopathies, congestive heart failure, and vascular dementia.
Hemostemix (HMTXF) has announced its first sales orders for ACP-01 Treatments following a social media campaign and presentations in Puerto Rico. The company has secured initial signed commitments amounting to $400,000 for 2025, with 11 months of selling ahead.
The company's CEO, Thomas Smeenk, highlighted that advanced sales help patients understand their treatment sequence and enable efficient scheduling of physician time and production. During recent meetings with physicians who have treated approximately 200 patients with ACP-01, an invasive cardiologist emphasized the unique effectiveness of ACP-01 in rebuilding heart function, stating it outperforms other autologous stem cell products specifically for cardiac applications.
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has announced its listing on the TradeGateExchange.De under symbol 2VF0, effective January 27, 2025. The company's management and directors have invested over $9.1 Million since 2020.
The company's product, ACP-01, has demonstrated safety across 498 treatments, with results documented in seven studies involving 318 subjects and nine peer-reviewed publications. The treatment shows efficacy in limb salvation, heart function regeneration, and mental acuity improvement.
The TradeGateExchange listing offers several benefits including extended trading hours, real-time market data, competitive fee structures, efficient order execution, and enhanced accessibility for European investors.
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) has announced its uplisting to the OTCQB market, commencing trading on January 23, 2025. The company's CEO, Thomas Smeenk, is presenting 'Welcome to Your Fountain of Youth!' at the Sequire Investor Summit.
Management and directors have invested over $9.1 Million in Hemostemix since 2020. The company's ACP-01 therapy has demonstrated success in saving limbs from amputation, regenerating heart function, and mental acuity, with safety proven across 498 treatments. These results are documented in seven studies involving 318 subjects and nine peer-reviewed publications.
The OTCQB listing is expected to bring multiple benefits including increased transparency, higher liquidity, broader investor access, enhanced market visibility, and improved corporate governance standards.
Hemostemix (TSXV: HEM) (OTC: HMTXF) announces its participation in two Puerto Rico Investor Summits in January 2025. The company will showcase its ACP-01 therapy and global scale-up strategy at the Sequire Investor Summit and CytoImmune-hosted Event.
Key highlights include the company's Automated Cell Therapy System (ACTS), which can scale from $12 million in annual revenue to $144 million monthly. Each 10' x 10' clean room produces 2,880 ACP-01 therapies annually. The therapy demonstrates a 93.5% success rate in saving limbs from amputation for chronic limb-threatening ischemia patients, reducing the five-year mortality rate from 60% to near zero.
Through partnership with CytoImmune and leveraging Puerto Rico's ACT 60 program, Hemostemix aims to achieve 50% cost reimbursement for research conducted in Puerto Rico. The company projects an 80% reduction in healthcare costs per patient through ACP-01's healing capabilities.
Hemostemix (TSXV: HEM) (OTC: HMTXF) has announced that its common share purchases can now be settled via the Depository Trust Company (DTC). The company filed a disclosure document with OTC Markets on January 7, 2025, and expects to receive OTCIQ access and begin trading on the OTCQB exchange later in January 2025.
The company has also entered into a 12-month agreement with biotech.de until December 31, 2025, to expand its reach to German-speaking investors. The services include German translation of news and social media, co-marketing, video production, investor introductions, and content creation to promote ACP-01 therapy for various conditions including PAD, CLTI, Angina, and various cardiac conditions. Biotech.de will receive compensation of $50,000 in Hemostemix common shares, issued quarterly at market price.
Hemostemix (HMTXF) has amended its Manufacturing Services Agreement with CytoImmune Therapeutics, adding Regulatory Consulting and Engineering Services. The agreement aligns with TSX Venture Exchange policies and Puerto Rico's ACT 60 Program. CytoImmune's regulatory expert, with FDA experience, will advise on regulatory strategy and clinical trials.
The partnership focuses on advancing Hemostemix's Automated Cell Therapy System (ACTS), capable of producing up to 2,880 ACP-01 therapies annually per clean room. At 80% efficiency with 10 production cells, the system could deliver 23,040 therapies yearly, priced at USD $37,000 each. The companies are studying production capacity at CytoImmune's 38,000-square-foot facility in San Juan.
Under the revised agreement, Hemostemix PR Inc. will make cash payments to CytoImmune, which will reinvest in Hemostemix's equity at market value. ACP-01 therapies target conditions including Peripheral Arterial Disease, Diabetic Foot Ulcers, and Critical Limb-Threatening Ischemia.
Hemostemix (TSXV: HEM) (OTC: HMTXF) has incorporated Hemostemix PR Inc. in Puerto Rico as a wholly owned subsidiary. Under Puerto Rico's ACT 60 program, the company is eligible for up to 50% cash reimbursement of R&D expenses, including clinical trials and economic impact assessments.
The company identifies an annual addressable market of 8,681 Diabetic Foot Ulcers treatments in Puerto Rico, valued at USD $37,000 each. This is based on Puerto Rico's diabetes prevalence of 19-20% among adults, affecting approximately 413,400 cases.
Clinical trial results show that ACP-01, the company's precision healthcare treatment, demonstrated significant efficacy: ulcer size decreased from 1.46 cm² to 0.48 mm² within three months in CLTI patients. In heart failure trials, ACP-01 improved cardiac function by up to 24.1% in ischemic cardiomyopathy and 47.1% in non-ischemic dilated cardiomyopathy patients at 12 months.
Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) has announced its application to up-list to the OTCQB Venture Market to increase liquidity across USA, European, and Canadian markets. The company is promoting its ACP-01 therapy through social media, highlighting successful patient treatments for limb salvation, heart function regeneration, and vascular dementia.
Clinical results show significant efficacy: 83% of patients in a Phase II trial experienced healing of ulcers and resolution of ischemic rest pain over 4.5 years. In dilated cardiomyopathy patients, cardiac function improved by up to 47.1% after one treatment. The Phase II results demonstrated ulcer size reduction from 1.46 cm² to 0.48 mm² within three months (p = 0.01).
The company addresses a significant market, with 236 million people suffering from peripheral arterial disease, of which 23 million develop chronic limb threatening ischemia with a 60% five-year mortality rate.
Hemostemix (TSXV: HEM) (OTC: HMTXF) announces growing traction in its social media awareness campaign across multiple platforms, promoting its trademarked "Your Fountain of Youth"™ regenerative medicine treatments. The campaign shares patient success stories and educates about innovative treatments for no-option cardiovascular diseases.
The company's ACP-01 treatment, derived from patients' blood and cultured in their serum, has shown significant results:
- In dilated cardiomyopathy patients, cardiac function improved by up to 47.1% after one treatment
- For Chronic Limb Threatening Ischemia (CLTI), 83% of patients followed for up to 4.5 years experienced healing of ulcers and pain resolution
- Ulcer size decreased significantly from 1.46 cm² to 0.48 mm² within three months in phase II trials
Hemostemix (TSXV: HEM) (OTC: HMTXF) has launched a comprehensive social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X to showcase patient success stories and educate about their regenerative medicine treatments. The company's flagship treatment, ACP-01, derived from patients' own blood and cultured in their serum, has demonstrated significant clinical results:
In dilated cardiomyopathy patients, cardiac function improved by up to 47.1% after one treatment, with notable improvements in severe cases. For Chronic Limb Threatening Ischemia (CLTI) patients, 83% experienced healing of ulcers and resolution of ischemic rest pain in follow-ups up to 4.5 years. Ulcer size decreased significantly from 1.46 cm² to 0.48 mm² within three months.